GlassScriptPhysician profile
Sukhraj Singh
NPI 1316224579
$11,545.89
in general payments reported to CMS, 2019-2025
30 companies · $3,467 in 2025
The $3,467 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.69 · 2022: $708 · 2023: $3,527 · 2024: $3,823 · 2025: $3,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,683.90 |
| Education | $134.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,003.23 | 2022-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $1,421.71 | 2022-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,338.77 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $845.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $788.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $651.62 | 2022-2025 | Benlysta, Nucala |
| Ucb, INC. | $634.77 | 2022-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $566.48 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $555.76 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $530.23 | 2022-2025 | Taltz |
| Ani Pharmaceuticals, INC. | $314.51 | 2023-2024 | Purified Cortrophin Gel |
| Ferring Pharmaceuticals INC. | $248.86 | 2022-2025 | Euflexxa |
| Genzyme Corporation | $229.88 | 2023-2025 | |
| Horizon Therapeutics Plc | $180.64 | 2022-2023 | Krystexxa |
| Sobi, INC | $153.59 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $152.49 | 2022-2025 | Strensiq |
| Radius Health, INC. | $126.86 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.44 | 2024-2025 | Orencia |
| Neurometrix INC | $98.73 | 2023 | |
| Genentech USA, INC. | $92.06 | 2022-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $91.44 | 2023 | Acthar |
| Sandoz INC. | $91.17 | 2023-2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $70.00 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $67.11 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $37.79 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2024 | Cyltezo |
| Organon LLC | $31.02 | 2024 | |
| Kyowa Kirin, INC. | $25.90 | 2025 | |
| Fresenius Kabi USA, LLC | $20.29 | 2024 | Idacio |
| Invivyd INC | $19.39 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhraj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.